Cannabis Seed Companies Stock

The legal marijuana industry is still in its infancy, and offers massive growth opportunities for investors. These pot stocks will have investors seeing green in the new year.

3 Cannabis Stocks That Are Better Buys Than Dogecoin

More than half of Grow Generation’s revenue comes from recurring sales of consumable products to cultivators.

Columbia Care’s acquisition strategy has turned it into one of the country’s larger MSO’s, and its revenue growth outlook is stellar.

OTC: CCHWF

Columbia Care Inc.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The legal marijuana industry is still in its infancy, and offers massive growth opportunities for investors.

While cryptocurrencies have intrigued at least a portion of the public — including people who don’t typically invest in stocks — it was tweets from Tesla CEO Elon Musk, billionaire entrepreneur Mark Cuban, and rap icon Snoop Dogg that cemented Dogecoin‘s reputation as the so-called “people’s currency.”

So the token that started as a joke has turned into a serious business. But considering that one of Dogecoin’s co-creators still believes it’s all smoke and mirrors, investors might want to put their money in something a little more grounded and tangible. Something, for example, like the legal cannabis industry, which is still just beginning to develop toward its full potential.

We asked three of our contributors to suggest marijuana stocks that would make better investments right now than Dogecoin. Their picks: GrowGeneration (GRWG 1.46% ) , Ayr Wellness (AYRW.F -1.15% ) , and Columbia Care (CCHWF -6.38% ) .

Image source: Getty Images.

It pays to sell what marijuana producers need

Alex Carchidi (Grow Generation): In my view, practically any company that makes products that people need is a better bet as an investment than Dogecoin. In the context of the cannabis industry, there’s a big need for the hydroponics equipment and greenhouse supplies that cultivators use to grow their crops indoors. That’s where Grow Generation comes into play.

The company is narrowly profitable, and it has a large and expanding footprint of nearly 60 retail locations, most of them in high-intensity cannabis markets like California, Colorado, and Michigan. Thanks to its strategy of focusing on these markets, its revenues are shooting upward: Its top line rose by 189.7% year over year in the second quarter.

In 2020, roughly 60% of its revenue came from recurring sources — sales of consumables like plant nutrients that cannabis cultivators need steady supplies of. As the industry continues to become more established in the U.S., Grow Generation will be able to keep building its base of consistent revenue, which should be great for its shareholders.

On Oct. 7, the company signed a distribution agreement to sell a yield-enhancing root health solution made by Groundwork BioAg. Investors can expect Grow Generation to keep expanding its product line and constructing new stores in up-and-coming markets.

The company is growing its revenue rapidly and proving that it can generate more money than it spends, all while organizing its resources for growth using an intelligent strategy. Whereas Dogecoin is an unpredictable joke cryptocurrency, Grow Generation is a real and thriving business. Between these two investment options, there isn’t even a contest.

Image source: Getty Images.

An under-the-radar winner

Eric Volkman (Ayr Wellness): There are a host of multi-state operators in the marijuana industry — and not all will survive. Those most likely to are the ones that have advantages of scale, cash, geography, or a combination of those factors. Relatively small Ayr Wellness lacks the first of those advantages, but the ambitious retailer certainly has cash and geography on its side.

Ayr is one of a host of publicly traded MSOs in the U.S. building out scale in order to profit from the rapid spread of cannabis legalization. At the moment, it has retail locations in six strategic marijuana states, and it will move into another shortly with its pending acquisition of two-store operator Herbal Remedies Dispensaries in Illinois.

The current locations of Ayr dispensaries already form an appealing mix. Some are in Massachusetts and Arizona — states that recently made recreational use legal and are seeing robust early growth. New Jersey very recently flipped the recreational switch and should see an explosion of pent-up demand. And Ayr is active in Nevada, a well-established and dependable market.

See also  99 Problems Cannabis Seeds

Finally, it has a presence in Pennsylvania and Florida — two populous states where cannabis is legal only for medical use, but which are likely to sanction recreational weed before long. (The company also has cultivation and production assets — but no dispensaries — in Ohio.)

A common way to build scale in the weed world is through acquisitions, and Ayr’s recent moves show it to be a smart and strategic buyer. Earlier this month, it closed its purchase of privately held PA Natural Medicine, adding three dispensaries to its count in Pennsylvania, and in September it took over GSD (which stands for “Garden State Dispensary”), one of only 12 vertical marijuana business license-holders in New Jersey.

It’s also acquisitive on the product side — it recently made a $20 million deal for THC-infused seltzer maker Cultivauna.

Ayr likes to buy stuff, but it’s not profligate. At the end of its most recently reported quarter, it had $153 million in cash on hand, down from $246 million in the preceding quarter, but well above the modest levels of less than $30 million it tended to hold as recently as last year.

The company is getting something for its money. In Q2, its revenue soared by 222% year over year and 56% sequentially — excellent numbers even among the high-growth tier of pot companies — while non-GAAP (adjusted) EBITDA improved by 225% and 49%, respectively.

Ayr’s net losses are admittedly still steep — and getting steeper. In Q2, it lost $37 million, compared to its prior-year shortfall of $24 million. But in terms of revenue, it’s headed in the right direction, and it has a decent-size cash cushion. It’s one of the smaller players on the scene, but that makes it a bit of a sleeper stock — and a far better investment than a shaky cryptocurrency.

Image source: Getty Images.

The market is mispricing this MSO

Rich Duprey (Columbia Care): While Dogecoin has a lot more buzz, investors might want to take a look instead at putting some money into Columbia Care, a small-cap MSO that ought to profit regardless of whether legalization at the federal level happens or not.

Columbia Care is trying to get to scale as quickly as possible in the event cannabis legalization occurs nationally, but also to take advantage of the opportunities that exist amid the current patchwork quilt of state regulations. It acquired vertically integrated medical marijuana dispenser Green Leaf Medical, the Ohio-focused four-dispensary operation CannAscend, and Project Cannabis, a California-based cultivator, wholesaler, and retailer.

Through its acquisition strategy, Columbia Care has turned itself into one of the largest MSOs around with 99 dispensaries and 31 cultivation and manufacturing facilities; it’s licensed to operate in 18 of the 36 states where marijuana has been legalized to some extent.

Columbia Care also just entered Virginia’s new medical marijuana market with some of the state’s first whole-flower sales for patients under its under Seed & Strain and gLeaf brands. The Virginia news is important because it underscores how the MSO is looking at its growth opportunities.

According to Columbia Care, when states expand opportunities for marijuana use within their borders — such as going from only allowing medical use to including recreational usage — its revenues tend to triple or quadruple in those markets. Virginia has plans to start allowing recreational weed sales a few years from now.

The MSO is targeting markets where it expects it will be able to get the most bang for its buck: high-volume states like California and Colorado; densely populated ones such as New York and New Jersey; and limited-license markets such as Ohio, Pennsylvania, and Illinois.

Wall Street likes what it sees. Analysts forecast that Columbia Care’s revenue will surge seven-fold over the next few years, growing from $180 million last year to as much as $1.45 billion in 2024. Yet Columbia Care’s stock is down 40% year to date. That seems like a huge mismatch with its potential.

See also  Maine Cannabis Seeds

Alex Carchidi has no position in any of the stocks mentioned. Eric Volkman has no position in any of the stocks mentioned. Rich Duprey has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Ayr Wellness, GrowGeneration Corp, and Tesla. The Motley Fool has a disclosure policy.

The 5 Best Marijuana Stocks to Buy in 2022

Global cannabis sales should double by 2026 to $62.1 billion, with the U.S. accounting for most of this growth.

OTC: TCNNF

Trulieve Cannabis

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

These pot stocks will have investors seeing green in the new year.

For many investors, the new year brings new opportunities to find attractive stocks in high-growth industries. Among all the industries to choose from, there may not be a better blend of growth and value at the moment than cannabis stocks, specifically those in the United States.

According to estimates from cannabis analytics company BDSA, worldwide weed sales are expected to double from $31 billion in 2021 to $62.1 billion by 2026. The bulk of this nominal growth will originate in the United States.

Although marijuana stocks were a buzzkill last year after federal cannabis-reform measures once again failed to gain traction in Congress, they’re now about as inexpensive as they’ve ever been. With that being said, these are the five best marijuana stocks to buy in 2022.

Image source: Getty Images.

Trulieve Cannabis

The easiest way to see green in the cannabis space is to buy the most nominally profitable pot stock: Trulieve Cannabis (TCNNF -1.23% ) .

Trulieve, like many of the stocks on this list, is a vertically integrated multi-state operator (MSO) that controls most aspects of the seed-to-sale process. But its path to profitability was a lot different than that of most pot stocks.

Instead of setting up shop in as many legalized states as possible, Trulieve focused most of its attention on Florida’s medical marijuana market. As of Dec. 30, Trulieve had 160 operating dispensaries nationwide, 112 of which were in the Sunshine State. Saturating Florida has allowed Trulieve to gobble up half of the state’s dried cannabis flower and oils market, all while keeping its marketing budget relatively low. The result: three consecutive years of profitability in an industry where only a handful of companies are currently profitable.

The excitement for 2022 revolves around Trulieve’s acquisition of MSO Harvest Health & Recreation, which was completed during the fourth quarter. Harvest Health’s home market is Arizona, which voted to legalize recreational weed in November 2020, and began retailing adult-use cannabis in January 2021. Trulieve has 17 dispensaries in the state and a clear pathway to leading market share.

With sales growth expected to top 50% in 2022, Trulieve looks like a bargain at roughly 26 times estimated earnings per share.

A hydroponic cannabis farm. Image source: Getty Images.

GrowGeneration

Ancillary cannabis plays haven’t fared nearly as well as I or other pundits would have expected. But one that looks ripe for the picking in 2022 is GrowGeneration (GRWG 1.46% ) .

GrowGen, as the company is better known, operates retail hydroponic and organic gardening centers in 13 states. Though the hydroponic (i.e., growing plants in a nutrient-rich water solvent), soil, nutrient, and lighting solutions offered by the company are helpful for consumers and enterprises of all industries, it’s of particular use to increasing crop yields for cannabis growers. Thus GrowGen is often viewed as a marijuana stock.

The company’s key to success has long been its aggressive acquisition strategy. Don’t get me wrong: GrowGen’s same-store sales have consistently risen by a double-digit percentage. However, the company’s bread and butter is acquiring locations in new and existing markets to quickly grow its brand.

In addition to acquisitions, management is focused on building up the company’s online presence, as well as promoting a number of proprietary and private-label brands that should provide a margin lift. The third quarter saw private-label and proprietary merchandise account for nearly 9% of total sales, which compares to more like 2% in the year-ago quarter.

See also  Cannabis Sativa Seed Oil Lotion

After getting pummeled last year, shares of GrowGeneration can be scooped up for well under two times estimated sales for 2022.

The Planet 13 Las Vegas SuperStore. Image source: Planet 13.

Planet 13 Holdings

The best marijuana stocks to buy in 2022 are those that provide a competitive advantage and differentiation. Small-cap MSO Planet 13 Holdings (PLNH.F -2.10% ) fits that description well.

What makes Planet 13 unique is that the company is focused just as much on providing a memorable experience for cannabis enthusiasts as it is on making sales. The key differentiator here is the sheer size and functionality of its dispensaries.

Planet 13 has two operating dispensaries at the moment. The Las Vegas SuperStore spans 112,000 square feet and features a cafe, consumer-facing processing center, and events center, to go along with the biggest selection of pot products you’ll find in any U.S. dispensary. There’s also the Orange County SuperStore in Santa Ana, California, which spans 55,000 square feet, including 16,500 square feet of selling space.

Having visited the Las Vegas SuperStore, I was impressed by the incorporation of technology (self-pay kiosks), a store layout that funnels customers to higher-margin derivative products, and the provision of individual budtenders to meet customer needs.

The next tourist-heavy locations for Planet 13 dispensaries will be Chicago; Orlando, Florida, and Miami.

With the company on the verge of recurring profitability and gobbling up a significant portion of Nevada’s weed sales with just a single location, it has the look of a no-brainer buy.

Image source: Getty Images.

Jushi Holdings

Another small-cap pot stock with serious potential in 2022 is MSO Jushi Holdings (JUSHF -3.63% ) .

To keep with the theme here, Jushi has a unique two-pronged strategy for growth.

First, it’s targeting a number of limited-license markets, like Pennsylvania, Illinois, Massachusetts, and Virginia. A limited-license state limits how many dispensary licenses are issued in total and/or to a single business. For big companies with deep pockets, limited-license markets can be a nuisance. But for Jushi, which has just 28 operating dispensaries nationwide, these limitations provide some degree of protection, allowing it to build up its brands and garner a loyal following.

Jushi’s other key catalyst has been prudently deploying cash for acquisitions. For example, the company acquired two dispensaries in Southern California last year. Though California has plenty of pot stores, it’s the leading market for marijuana sales in the world.

As a Jushi shareholder, I’ll also add that execs and other insiders were responsible for contributing $45 million of the first $250 million in capital raised by the company. When the financial interest of insiders align with that of shareholders, good things happen more often than not.

Image source: Getty Images.

Cresco Labs

The fifth and final best marijuana stock to buy in 2022 is MSO Cresco Labs (CRLBF -4.58% ) .

Similar to Jushi Holdings, Cresco Labs has a penchant for focusing most of its attention on limited-license states, at least with regard to its retail operations. The company has 45 operating dispensaries, with a presence in limited-license markets like Illinois, Ohio, and Massachusetts. Mixing in competitive high-dollar markets, such as Florida, with limited-license markets gives Cresco a path to sustainable double-digit retail growth.

But what really allows Cresco Labs to stand out is the company’s industry-leading wholesale operations. Wall Street isn’t a big fan of wholesale cannabis because the margins aren’t anything to speak of next to retail cannabis. But Cresco Labs can make up what it loses in margin with insane volume. That’s because it holds one of only a small handful of cannabis distribution licenses in California. This license allows it to place its proprietary pot products into more than 575 dispensaries throughout the Golden State.

Cresco Labs has all the tools and momentum necessary to reach recurring profitability in 2022. With the company now valued at well under two times estimated sales (per Wall Street) this year, it looks like a budding bargain.

Sean Williams owns Jushi Holdings. The Motley Fool owns and recommends Cresco Labs Inc., GrowGeneration Corp, Jushi Holdings, Planet 13 Holdings Inc., and Trulieve Cannabis Corp. The Motley Fool has a disclosure policy.